Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:naphthoylindole
synthetic cannabinoid |
| gptkbp:agonist_of |
gptkb:CB1_receptor
gptkb:CB2_receptor |
| gptkbp:binding_affinity_(CB1) |
9 nM
|
| gptkbp:binding_affinity_(CB2) |
2.94 nM
|
| gptkbp:CASNumber |
209414-07-7
|
| gptkbp:chemicalFormula |
C25H25NO
|
| gptkbp:discoveredBy |
gptkb:John_W._Huffman
|
| https://www.w3.org/2000/01/rdf-schema#label |
JWH-019
|
| gptkbp:IUPACName |
1-hexyl-3-(naphthalen-1-oyl)indole
|
| gptkbp:legal_status_in_UK |
Class B drug
|
| gptkbp:legalStatus |
Schedule I controlled substance (as a CB1 receptor agonist of the 3-(1-naphthoyl)indole class)
|
| gptkbp:molecularWeight |
355.48 g/mol
|
| gptkbp:namedAfter |
gptkb:John_W._Huffman
|
| gptkbp:PubChem_CID |
44418338
|
| gptkbp:relatedTo |
gptkb:JWH-018
gptkb:JWH-073 |
| gptkbp:routeOfAdministration |
oral
smoked |
| gptkbp:used_in |
scientific research
|
| gptkbp:bfsParent |
gptkb:JWH_cannabinoids
|
| gptkbp:bfsLayer |
6
|